NCT01496976View on ClinicalTrials.gov

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 30, 2012

Primary Completion Date

October 6, 2021

Study Completion Date

September 11, 2024

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

High Dose Methylprednisolone (HDMP)

HDMP will be administered at 1 gm/m\^2 IV over 90 minutes daily with ofatumumab infusions 1-8.

DRUG

Ofatumumab

Ofatumumab infusion will be administered immediately after HDMP.

DRUG

Lenalidomide

The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER